Thursday May 25th 2017

Policy groups decry GOP-led funding proposal for Medicaid

Adrianne Gunther was a senior at the University of the Arts in Philadelphia when her symptoms began — first an inability of focus and an overwhelming sense of confusion, and then soon after graduating, a loss of vision in her left eye. A neural ophthalmologist diagnosed her with optic neuritis, telling her that it was one of the first signs of multiple sclerosis, a debilitating autoimmune disea se that causes lesions to form on the brain and in the spinal cord, interrupting nerve pathways and causing… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Source:  

Policy groups decry GOP-led funding proposal for Medicaid

Leave a Comment

More from category

MS Study Alert: Share Your Thoughts About MS Research
MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS
Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS
First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows
Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint
Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]